News | May 24, 2025
Glenmark Pharma reports Q4 FY25 PAT at Rs. 346.6 Cr
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
For the full year FY25, net profit soared 12x to Rs 345 crore
Allopurinol is used to prevent or lower high uric acid levels in the blood
Amlodipine and Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
Subscribe To Our Newsletter & Stay Updated
